Search results for "Nous"

showing 10 items of 2193 documents

Prevalence of surrogate markers of relative energy deficiency in male Norwegian Olympic-level athletes

2021

Author's accepted manuscript. Accepted author manuscript version reprinted, by permission, from [International Journal of Sport Nutrition and Exercise Metabolism, 2021, 31(6): 497-506, https://doi.org/10.1123/ijsnem.2020-0368]. © Human Kinetics, Inc. The syndrome of Relative Energy Deficiency in Sport (RED-S) includes wide-ranging effects on physiological and psychological functioning, performance, and general health. However, RED-S is understudied among male athletes at the highest performance levels. This cross-sectional study aimed to investigate surrogate RED-S markers prevalence in Norwegian male Olympic-level athletes. Athletes (n = 44) aged 24.7 ± 3.8 years, body mass 81.3 ± 15.9 kg,…

AdultMaleMedicine (miscellaneous)PhysiologyNorwegianRC1200Young AdultPrevalenceMedicineHumansRelative Energy Deficiency in SportOrthopedics and Sports MedicineTestosteroneSubclinical infectionBone mineralNutrition and Dieteticsbiologybusiness.industryAthletesGeneral MedicineVenous bloodbiology.organism_classificationlanguage.human_languageCross-Sectional StudiesAthletesBasal metabolic ratelanguageBody CompositionbusinessVDP::Samfunnsvitenskap: 200::Samfunnsvitenskapelige idrettsfag: 330BiomarkersRelative energy
researchProduct

Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma

2013

Abstract Background A combination of bortezomib (1.3 mg/m2), melphalan (5 mg/m2), and dexamethasone (40 mg) (BMD), with all three drugs given as a contemporary intravenous administration, was retrospectively evaluated. Patients and methods Fifty previously treated (median 2 previous lines) patients with myeloma (33 relapsed and 17 refractory) were assessed. The first 19 patients were treated with a twice-a-week (days 1, 4, 8, 11, ‘base’ schedule) administration while, in the remaining 31 patients, the three drugs were administered once a week (days 1, 8, 15, 22, ‘weekly’ schedule). Results Side-effects were predictable and manageable, with prominent haematological toxicity, and a better tox…

AdultMaleMelphalanmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSalvage therapyGastroenterologyDexamethasoneDisease-Free SurvivalDrug Administration ScheduleBortezomibRefractoryRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalMelphalanMultiple myelomaDexamethasoneAgedRetrospective StudiesAged 80 and overBortezomibbusiness.industryHematologyMiddle Agedmedicine.diseaseBoronic AcidsRegimenTreatment OutcomeOncologyPyrazinesInjections IntravenousFemaleMultiple MyelomabusinessFollow-Up Studiesmedicine.drug
researchProduct

Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application

1994

Pharmacokinetics and bioavailability of benperidol were determined in 13 schizophrenic patients after acute administration of 6 mg benperidol as an intravenous (i.v.) bolus injection, orally as liquid, and orally as tablets using a partially randomized cross-over design. Drug plasma levels were determined by high performance liquid chromatography with electrochemical detection and subjected to model independent pharmacokinetic analyses. After i.v. dosing the geometric means (mean-g) were 3.2 min for the distribution half-life, 5.80 h for the elimination half-life (t1/2 beta), 4.21 l/kg for the distribution volume, 7.50 h for the mean residence time (MRT), and 0.50 l/(h*kg) for the clearance…

AdultMaleMetaboliteAdministration OralBiological AvailabilityPharmacologyHigh-performance liquid chromatographyBenperidolchemistry.chemical_compoundPharmacokineticsOral administrationmedicineHumansDistribution (pharmacology)PharmacologyCross-Over StudiesChemistryBenperidolMiddle AgedBioavailabilityInjections IntravenousSchizophreniaFemaleGeometric meanOxidation-ReductionHalf-Lifemedicine.drugPsychopharmacology
researchProduct

Relationship Between Regional Cerebral Blood Flow and Electrocorticographic Activities Under Sevoflurane and Isoflurane Anesthesia

2010

The aims of this study are (1) to assess the effects of volatile anesthetics on regional cerebral blood flow (rCBF) and electrocorticography (ECoG), and (2) to investigate the relationship between rCBF and ECoG influenced by volatile anesthetics. The authors measured rCBF using laser Doppler flowmetry and ECoG simultaneously and continuously from the same cortex during craniotomy, using the specially arranged probe. Patients received intravenous anesthetics with nitrous oxide until craniotomy, and after opening of dura, volatile anesthetic, either isoflurane or sevoflurane, was started and was gradually increased for the measurement. Four of the nine cases (44.4%) of the sevoflurane group s…

AdultMaleMethyl EthersAdolescentPhysiologymedicine.medical_treatmentAnesthesia GeneralSevofluraneSevofluraneYoung AdultPhysiology (medical)mental disordersmedicineHumansPremovement neuronal activityneoplasmsElectrocorticographyCraniotomyAgedIsofluranemedicine.diagnostic_testbusiness.industryBrainElectroencephalographyMiddle AgedLaser Doppler velocimetrynervous system diseasesnervous systemNeurologyCerebral blood flowIsofluraneRegional Blood FlowCerebrovascular CirculationAnesthesiaAnesthetics InhalationAnestheticFemaleNeurology (clinical)businessAnesthetics IntravenousCraniotomycirculatory and respiratory physiologymedicine.drugJournal of Clinical Neurophysiology
researchProduct

The effects of arterial carbon dioxide partial pressure and sevoflurane on capillary venous cerebral blood flow and oxygen saturation during cranioto…

2009

Intraoperative routine monitoring of cerebral blood flow and oxygenation remains a technological challenge. Using the physiological principle of carbon dioxide reactivity of cerebral vasculature, we investigated a recently developed neuromonitoring device (oxygen-to-see, O2C device) for simultaneous measurements of regional cerebral blood flow (rvCBF), blood flow velocity (rvVelo), oxygen saturation (srvO2), and hemoglobin amount (rvHb) at the capillary venous level in patients subjected to craniotomy. METHODS: Twenty-six neurosurgical patients were randomly assigned to anesthesia with 1.4% or 2.0% sevoflurane end-tidal concentration. After craniotomy, a fiberoptic probe was applied on a ma…

AdultMaleMethyl EthersPartial PressureVasodilation610 Medicine & healthSevofluraneSevofluraneCerebral circulation10180 Clinic for NeurosurgeryMonitoring IntraoperativeLaser-Doppler FlowmetrymedicineHumansAgedbusiness.industryVenous bloodBlood flowOxygenationCarbon DioxideCerebral ArteriesMiddle AgedCerebral VeinsCapillariesOxygenAnesthesiology and Pain MedicineBlood pressureCerebral blood flowCerebrovascular CirculationAnesthesiaFemale2703 Anesthesiology and Pain MedicinebusinessCraniotomymedicine.drug
researchProduct

Prospective assessment of postoperative pain after craniotomy.

2010

Pain after craniotomy may be underdiagnosed, despite the fact that it can increase postoperative complications for example arterial hypertension and postoperative hemorrhage. This study investigates the incidence and intensity of pain after craniotomy and characterizes the influencing parameters. During a 1-year period 256 patients undergoing elective craniotomy were prospectively included in the study. Intensity of pain was evaluated 1, 4, and 24 hours after extubation using a verbal numerical rating scale (NRS) ranging from 0 (no pain) to 10 (maximal pain). Routine perioperative pain management was not influenced by the investigators. Parameters including patient-related factors, drug adm…

AdultMaleMethyl EthersPirinitramideAgingAdolescentCritical Caremedicine.medical_treatmentPostoperative painAnesthesia GeneralNeurosurgical ProceduresSevofluraneYoung AdultmedicineHumansProspective StudiesYoung adultProspective cohort studyCraniotomyAgedPain MeasurementAged 80 and overPain Postoperativebusiness.industryIncidence (epidemiology)BrainMiddle AgedAnalgesics OpioidAnesthesiology and Pain MedicinePostoperative diagnosisLogistic ModelsAnesthesiaAnesthetics InhalationAnesthesia IntravenousSurgeryFemaleNeurology (clinical)businessAnesthesia InhalationCraniotomyJournal of neurosurgical anesthesiology
researchProduct

Fatal sepsis due to mycobacterium tuberculosis after allogeneic bone marrow transplantation.

2001

Mycobacterium tuberculosis is a serious, but rare infectious complication after allogeneic bone marrow transplantation. We describe a case of fatal sepsis due to Mycobacterium tuberculosis after allogeneic bone marrow transplantation for Philadelphia chromosome-positive ALL. The diagnosis was made after BAL. Although broad-spectrum antituberculous therapy was started immediately after diagnosis, blood cultures became positive for Mycobacterium tuberculosis. The patient developed severe pyrexias and finally died of multi-organ failure. Rapid progression of mycobacterial infection should be considered in patients post BMT with unexplained fever, particularly in patients from endemic areas.

AdultMaleMycobacterium tuberculosisSepsisFatal OutcomeAcute lymphocytic leukemiamedicineHumansTransplantation HomologousTuberculosisIn patientAutogenous boneBone Marrow TransplantationTransplantationbiologybusiness.industryMarrow transplantationHematologyMycobacterium tuberculosisPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseasebiology.organism_classificationmedicine.anatomical_structureImmunologyBone marrowbusinessComplicationBone marrow transplantation
researchProduct

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015

Purpose Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accepted standard of care for patients with relapsed or refractory disease. This study evaluated the efficacy and tolerability of belinostat, a novel histone deacetylase inhibitor, as a single agent in relapsed or refractory PTCL. Patients and Methods Patients with confirmed PTCL who experienced progression after ≥ one prior therapy received belinostat 1,000 mg/m2 as daily 30-minute infusions on days 1 to 5 every 21 days. Central assessment of response used International Working Group criteria. Primary end point was overall response rate. Secondary end points included …

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsKaplan-Meier EstimateHydroxamic AcidsDisease-Free SurvivalDrug Administration Schedulechemistry.chemical_compoundRefractoryInternal medicineClinical endpointHumansMedicineInfusions IntravenousAgedAged 80 and overSulfonamidesbusiness.industryHistone deacetylase inhibitorLymphoma T-Cell PeripheralORIGINAL REPORTSMiddle Agedmedicine.diseaseLymphomaSurgeryHistone Deacetylase InhibitorsClinical trialTreatment OutcomePrior TherapyOncologyTolerabilitychemistryDrug Resistance NeoplasmFemaleNeoplasm Recurrence LocalbusinessBelinostatJournal of Clinical Oncology
researchProduct

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral b…

2001

We examined safety and efficacy of STI-571 in 24 bcr/abl-positive patients with CML post PBSCT. At start of STI-571 therapy, nine patients presented in blast crisis (BC) or in accelerated phase (AP), and 15 in chronic phase (CP). Patients were evaluated for hematologic, cytogenetic and molecular response, survival and toxicity. In general, STI-571 was well tolerated in this heavily pretreated group of patients with a non-hematologic and hematologic toxicity profile similar to that observed in a previous phase I trial at comparable doses. Five of nine patients with CML in transformation (AP, BC) were evaluable for hematologic response. Two of five patients had transient reductions in WBC and…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentFusion Proteins bcr-ablAntineoplastic AgentsPhiladelphia chromosomeTransplantation AutologousPiperazinesLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansEnzyme InhibitorsChemotherapyABLbusiness.industryHematopoietic Stem Cell Transplantationbreakpoint cluster regionHematologyMiddle AgedProtein-Tyrosine Kinasesmedicine.diseaseCombined Modality TherapyHematologic ResponseBlood Cell CountPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesToxicityImmunologyImatinib MesylateFemaleComplicationbusinessLeukemia
researchProduct

Adenocarcinoma of the appendix with extra-appendicular spread: Clinico-surgical and histologic analysis of 27 cases.

2017

Abstract Background and objectives Appendiceal neoplasms with extra-appendiceal spread may show different clinical patterns with pseudomyxoma peritonei (PMP) being one of them. We analyse the results in a series of patients treated in our centre. Material and methods Retrospective study of patients operated on for appendiceal peritoneal carcinomatosis from January 2012 to May 2015. Results Twenty-seven consecutive patients were included. Median age 63 years (26–73); 14 were men. Peritoneal carcinomatosis index = 16 ± 8 (3–31). The suspected preoperative origins were appendix in 23, ovary in 3 and urothelial in one. Postoperative mortality in 2 patients (7.4%). The remaining 36% presented mo…

AdultMaleOncologymedicine.medical_specialty030230 surgery03 medical and health sciencesPeritoneal NeoplasmAdenocarcinoma mucinoso Appendicular neoplasia Carcinomatosis peritoneal Hyperthermic intraperitoneal chemotherapy Mucinous adenocarcinoma Neoplasia apendicular Peritoneal carcinomatosis Pseudomixoma peritoneal Pseudomixoma peritonei Quimioterapia intraperitoneal hipertérmica0302 clinical medicineInternal medicineAscitesmedicineHumansPseudomyxoma peritoneiNeoplasm InvasivenessPeritoneal NeoplasmsAgedRetrospective Studiesbusiness.industryRetrospective cohort studyMiddle AgedPrognosisPseudomyxoma Peritoneimedicine.diseaseAdenocarcinoma MucinousAppendixmedicine.anatomical_structureAppendiceal Neoplasms030220 oncology & carcinogenesisAdenocarcinomaFemaleHyperthermic intraperitoneal chemotherapyRadiologymedicine.symptombusinessOvarian cancerFollow-Up Studies
researchProduct